<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1535">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01965600</url>
  </required_header>
  <id_info>
    <org_study_id>B5211007</org_study_id>
    <nct_id>NCT01965600</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model</brief_title>
  <acronym>POM</acronym>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, 2-Way Crossover Study To Evaluate The Safety And Pharmacodynamic Effects Of PF-06282999 Using An Endotoxin (Lipopolysaccharide) Induced Inflammatory Response Model In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An endotoxin challenge will be administered to healthy subjects to induce production of
      inflammatory markers.  An investigational drug or placebo will be administered prior to the
      endotoxin challenge to assess the effect of the investigational drug on the markers of
      inflammation. Safety and tolerability will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>MPO activity</measure>
    <time_frame>Day 1 Hr 0; Day 3 Hr 0, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 24, 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>Day 3 timepoints are post-LPS administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>Day 1 Hr 0; Day 3 Hr 2, 3, 4, 5, 6, 10, 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-1beta</measure>
    <time_frame>Day 1 Hr 0; Day 3 Hr 2, 3, 4, 5, 6, 10, 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>Day 1 Hr 0; Day 3 Hr 2, 3, 4, 5, 6, 10, 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-8</measure>
    <time_frame>Day 1 Hr 0; Day 3 Hr 2, 3, 4, 5, 6, 10, 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hs-CRP</measure>
    <time_frame>Day 1 Hr 0; Day 3 Hr 8, 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPO activity/MPO mass</measure>
    <time_frame>Day 1 Hr 0; Day 3 Hr 0, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 24, 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 3 Hr 0, 2, 3, 4, 5, 6, 8, 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau)</measure>
    <time_frame>Day 3 Hr 0, 2, 3, 4, 5, 6, 8, 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Day 3 Hr 0, 2, 3, 4, 5, 6, 8, 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06282999</intervention_name>
    <description>Tablet, 125 mg, TID, 3 days, 1 of 2 periods</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, 0 mg, TID, 3 days, 1 of 2 periods</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LPS</intervention_name>
    <description>IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Endotoxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06282999</intervention_name>
    <description>Tablet, 500 mg, BID, 3 days, 1 of 2 periods</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, 0 mg, BID, 3 days, 1 of 2 periods</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LPS</intervention_name>
    <description>IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Endotoxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men or women (non-childbearing potential) between the ages of 18-40 years.

          -  Body Mass Index (BMI) 18-30 kg/m2 and a total body weight &gt;50 kg (110 lbs).

        Exclusion Criteria:

          -  History or evidence of habitual use of tobacco- or nicotine-containing products
             within 3 months of screening.

          -  History of frequent headaches or migraines (&gt;3 per month), or headaches from an
             absence of caffeine.

          -  Caffeine consumption in excess of 3 cups per day.

          -  Subjects who have experienced cold/flu symptoms (ie, runny nose, cough, and/or fever)
             within 2 weeks of the first administration of study drug/placebo of each period.

          -  History of recurrent or chronic infections of any type such as tuberculosis,
             sinusitis, urinary tract infection, respiratory tract or dental (abscess) infection,
             etc.  Also excluded are subjects with recurrent oral or genital herpes, recurrent
             herpes zoster, or any infection otherwise judged by the investigator to have the
             potential for worsening if enrolled in this study.

          -  Treatment with LPS in the past 12 months and/or a history of an allergic type
             reaction or known hypersensitivity to endotoxin at any time.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5211007&amp;StudyName=A%20Study%20To%20Evaluate%20The%20Safety%20And%20Effects%20On%20The%20Body%20Of%20An%20Investigational%20Drug%20Using%20An%20Endotoxin-Induced%20Inflammatory%20Response%20Mod</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>October 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endotoxin challenge</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
